Using their Ligand Activated Therapy (LAT) platform, KemPharm discovers and develops prodrugs that enhance the attributes of approved drugs, such as abuse resistance and safety. They are currently working on KP415, KP484, and KP879, which are prodrugs based on d-methylphenidate. With a patient-centric approach, KemPharm collaborates with key stakeholders to ensure effective clinical and regulatory strategies. By embracing innovative solutions and unbiased data analysis, they overcome complex challenges to provide much-needed therapies and improve patients' lives.